These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15953079)

  • 1. Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
    Alexandrescu DT; Koulova L; Wiernik PH
    Clin Exp Dermatol; 2005 Jul; 30(4):391-4. PubMed ID: 15953079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
    Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
    Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
    Martin MG; Vij R
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
    Prasad HK; Kaushal V; Mehta P
    Am J Hematol; 2007 Sep; 82(9):855-7. PubMed ID: 17570510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
    South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma.
    Serefhanoglu S; Haznedaroglu IC; Goker H; Buyukasik Y; Ozcebe OI
    Onkologie; 2009 Nov; 32(11):662-4. PubMed ID: 19887870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desensitization to thalidomide in a patient with multiple myeloma.
    Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell leukaemia mimicking acute monocytic leukaemia in the course of multiple myeloma.
    Eclache V; Lusina D; Lejeune F; Casassus P; Smadja N; Lortholary P
    Nouv Rev Fr Hematol (1978); 1993 Aug; 35(4):419-22. PubMed ID: 8414961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 14. [Contemporaneous presentation of plasma cell leukemia and multiple myeloma. Description of a clinical case with a biclonal component].
    Pasqualetti P; Casale R; Colantonio D; Natali G
    Minerva Med; 1987 Jul; 78(13):907-10. PubMed ID: 3601136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kappa light chain myeloma with initial cutaneous involvement.
    Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK
    Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophilic dermatosis complicating lenalidomide therapy.
    Thieu KP; Rosenbach M; Xu X; Kist JM
    J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.
    Ballanti S; Mastrodicasa E; Bolli N; Lotti F; Capolsini I; Berchicci L; Merigiola C; Giordano G; Tabilio A
    Nat Clin Pract Oncol; 2007 Dec; 4(12):722-5. PubMed ID: 18037876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
    J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.